Poly (N-vinyl formamide) market was valued at US$ 397.89 Mn million in 2024 and is projected to hit the market valuation of US$ 633.85 million by 2033 at a CAGR of 5.31% during the forecast period ...

The Global Synthetic Biology Market is estimated to be valued at USD 13.83 billion in 2023 and is projected to expand at a robust Compound Annual Growth Rate (CAGR) of 17.30% over the forecast period ...

Pharmaceutical water is a crucial component in the manufacturing, processing, and formulation of pharmaceutical products. It must meet stringent regulatory standards to ensure its purity, sterility, ...

Rapid Micro Biosystems Inc (RPID) reports a 30% revenue increase and unveils a promising partnership with Millipore Sigma, despite ongoing financial challenges.

Aldrich Potgieter, age 20, is on the verge of becoming the sixth youngest winner in PGA Tour history. The young golfer has already set a new tournament 54-hole scoring record at 20-under 193. Last ...

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader drug portfolio continues to perform well and is driving a strong earnings ...

It's been a rough start to 2025 for Merck (NYSE: MRK) shareholders following a less-than-stellar fourth-quarter earnings report. Even as the pharmaceutical giant exceeded Wall Street estimates ...

Lawsuits surrounding Merck's HPV vaccine Gardasil have been piling up for years now, but they've garnered increased public attention lately after HHS Secretary Robert F. Kennedy Jr.'s links to the ...

Merck & Co.’s first trial over the safety of its blockbuster Gardasil cancer vaccine was cut short and rescheduled amid concerns that jurors might be influenced by controversy this month around ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other cheap high dividend stocks. According to Deutsche Bank Wealth Management, the global ...

Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg. Gilead had the right to ...